Drug intelligence / Profile preview

MUC1 peptide vaccine + SB-AS2

Development stage: Unknown
Lead developer: University of Pittsburgh
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

This is a peptide-based cancer vaccine developed by the University of Pittsburgh for the treatment of pancreatic cancer. The vaccine consists of a 100-amino acid synthetic peptide representing five 20-amino acid tandem repeats of the MUC1 protein, which is frequently overexpressed and hypoglycosylated in pancreatic tumors. To enhance immunogenicity, the peptide is formulated with the SB-AS2 adjuvant system, a combination of monophosphoryl lipid A (MPL) and the saponin QS-21. In Phase I clinical trials, the vaccine was evaluated for its safety and ability to elicit MUC1-specific T-cell and antibody responses in patients with resected or locally advanced pancreatic cancer.

Other names: MUC1 antigen/SB AS-2100 aa synthetic Mucin peptide vaccineMUC1-SB-AS2MUC-1-SB-AS2MUC 1-SB-AS2MUC1 antigen + SB AS-2-University of Pittsburgh-pancreatic cancer

Targets

MUC1 (Mucin-1 Antigen)

Beyond the preview

Go deeper on MUC1 peptide vaccine + SB-AS2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MUC1 peptide vaccine + SB-AS2.

Explore the full profile